Search
Close
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Biothreat Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Biothreat Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Biothreat Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19 OUS
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Biothreat Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19 OUS
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources
  • Investors
  • Technical Support
  • Contact Us
Menu
  • Investors
  • Technical Support
  • Contact Us
  • Investors
  • Contact Us
Menu
  • Investors
  • Contact Us
Schedule a Meeting
Search
Close
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Biothreat Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Dx Instrument
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Biothreat Panel
    • T2SARS-CoV-2 Panel
    • T2MR Technology
    • Product Pipeline
      • BARDA
      • T2Resistance Panel
      • T2Lyme Panel
      • T2Cauris Panel
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19
    • Lyme Disease
  • Resources
    • Publications
    • Case Studies
    • Webinars & Videos
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships
    • International Distributors
    • FAQ
    • Media Resources
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Biothreat Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19 OUS
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources
Menu
  • Products & Technology
    • T2Bacteria Panel
    • T2Candida Panel
    • T2Resistance Panel
    • T2Biothreat Panel
    • T2Dx Instrument
    • T2MR Technology
    • Product Pipeline
      • T2Lyme Panel
      • T2Cauris Panel RUO
  • Healthcare Challenges
    • Sepsis
    • Antimicrobial Resistance
    • COVID-19 OUS
    • Lyme Disease
  • Resources
    • Publications
    • Webinars & Videos
    • Case Studies
  • About T2
    • Our Company
    • Our Mission
    • News
    • Leadership
    • Careers
    • Events
    • Research Partnerships International
    • Distributors
    • FAQ
    • Media Resources

Publication Year: 2018

T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study

T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study

Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study

T2Bacteria magnetic resonance assay for the rapid detection of ESKAPEc pathogens directly in whole blood

Accuracy of T2MR in diagnosing candidemia in critically ill patients: a prospective observational study

T2Candida® to guide antifungal and length of treatment of candidemia in a pediatric multivisceral transplant recipient

Implementation of the T2 Biosystems T2Bacteria Panel in a level-one trauma center, safety net hospital

Incorporating T2Candida testing into rational antifungal (AF) management: A successful pilot study of diagnostic stewardship directed toward specific intensive care unit patients at-risk for sepsis due to invasive candidiasis

T2Candida (T2MR) versus Beta-D-Glucan for preemptive antifungals stewardship in the intensive care unit

Impact of T2Candida Panel on species specific antifungal de-escalation

Novel T2Candida Panel assay compared to blood cultures for detection of candidemia in transplant and non-transplant patients

Diagnosing candidemia with the T2Candida Panel: An instructive case of septic shock in which blood cultures were negative

← older

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

© 2022 T2 Biosystems, Inc.

JOIN IN ON TWITTER

T2 Biosystems
@T2Bio

Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.

  • March 31, 2023
T2 Biosystems
@T2Bio

Given the high attributable mortality and challenges with conventional diagnostic methods, the need for improved #rapiddiagnostics for #Candida species is evident. #whitepaper #diagnostics #fungi #fungalinfection #sepsis

  • March 30, 2023

SITEMAP

  • T2MR Technology
  • T2Bacteria Panel
  • T2Candida Panel
  • Product Pipeline
  • T2Dx Instrument
  • Terms of Use & Privacy Policy
  • Standard Terms & Conditions
Menu
  • T2MR Technology
  • T2Bacteria Panel
  • T2Candida Panel
  • Product Pipeline
  • T2Dx Instrument
  • Terms of Use & Privacy Policy
  • Standard Terms & Conditions

FOLLOW US ON SOCIAL

Linkedin-in Twitter
  • About T2
  • Investors
  • Technical Support
  • Careers
  • Contact Us
  • Conflict Minerals Report
  • T2 Compliance Program
  • Declaration of Compliance
Menu
  • About T2
  • Investors
  • Technical Support
  • Careers
  • Contact Us
  • Conflict Minerals Report
  • T2 Compliance Program
  • Declaration of Compliance

Please tell us where you are visiting from: United States | Outside the United States